A noval vaccine formulation consisting of DNA vaccine inactivated virus

Disclosed herein is a novel vaccine formulation for prophylactic or therapeutic immunization of vertebrates against infections caused by vertebrate viruses. The said vaccine contains a min. of two components, one of which is a deoxyribonucleotide (DNA) vaccine comprising of a DNA mol. that encodes a polypeptide of the virus and the other component consisting of inactivated form of the virus. This invention can also be used to develop low cost inactivated virus-based vaccines that contain much lower amt. of the said virus than that present in similar vaccines known in the prior art. The examples focus on the methods of producing a novel vaccine compn. against the rabies virus

Assessment of immunoprophylactic efficacy of recombinant mid gut antigen (Bm95) of Rhiphicephalus microplus in Bos indicus

Use of recombinant Bm95 isolated from an Argentinean strain of Rhiphicephalus microplus A as a vaccine candidate to control the tick infestation in India was investigated. Recombinant Bm95 expressed in yeast, Pichia pastoris. Purified protein blended into a vaccine using aluminium hydroxide as an adjuvant. An adverse effect on the reproduction of ticks was observed in vaccinated animals indicating reduced the environmental contamination and source of infestation indicating its use of Bm95 in the immunological control of ticks in India

Recombinant mid gut antigen (Bm95) as a vaccine against Indian Rhiphicephalus haemaphysaloides in Bos indicus cattle

In the present study, we report for the first time the efficacy of recombinant Bm95 mid gut antigen isolated from an Argentinean strain of Rhipicephalus microplus strain A in controlling the tick infestations in India. The synthetic gene for Bm95 optimized for expression in yeast was obtained and used to generate yeast transformants expressing Bm95 which was purified to apparent homogeneity. Liquid chromatography-mass spectrometry analysis of the purified protein confirmed its identity as Bm95. Vaccine was prepared by blending various concentrations of purified Bm95 with aluminium hydroxide as an adjuvant. lmmunogenicity studies of the vaccine in rabbits and cattle indicated that the vaccine was highly immunogenic. The efficacy studies of the vaccine was done in cattle. Naive Bos indicus cattle were vaccinated with the recombinant vaccine and were challenged with the larval, nymphal and adult forms of Rhiphicephalus haemaphysaloides. The vaccine protected the animals from larval, nymph and adult tick challenges with an efficacy of 98.7%, 84.6% and 78.9% respectively. The results obtained from the above studies clearly demonstrated the advantage and possibilities of the use of Bm95 in controlling R. haemaphysaloides infestations in the field. (C) 2010 Elsevier Ltd. All rights reserved